Substituted 2,3-dihydro-1H-inden-1-one is a retinoic acid-related nuclear orphan receptor antagonist for the treatment of multiple sclerosis

• 收藏
• 分享

专利权人:

アーリーン ファーマシューティカルズ エルエルシー

发明人:

ヴァンカイアラパティ、ハリプラサド,ヤーラムレディー、ヴェンカタクリシュナレディー

申请号：

JP2018114836

公开号：

JP6574289B2

申请日:

2018.06.15

申请国别(地区):

JP

年份:

2019

代理人:

摘要：

The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the Retinoic acid-related orphan nuclear receptor &gamma；t (ROR&gamma；t)/ROR&gamma；. The compounds of the present invention are useful for modulating ROR&gamma；t)/ROR&gamma； activity and for treating diseases or conditions mediated by ROR&gamma；t)/ROR&gamma； such as for example, disease states associated with immunopathology of human autoimmune diseases such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Inflammatory Colitis, Psoriasis, COPD, Pain, Obesity, Diabetes, Dyslipidemia, Osteoporosis, Asthma, Neurodegenerative diseases and Cancer.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/